TREVENTIS Scientific Founder Donald Weaver, MD, Named 2009 Recipient of Prix Galien Canada Award for Outstanding Achievement in Development of New Medicines for Alzheimer's Disease

Published: Dec 16, 2009

PHILADELPHIA--(BUSINESS WIRE)--TREVENTIS Corporation announced today that the company’s scientific founder, Donald F. Weaver, MD, PhD, is the recipient of the 2009 Prix Galien Research Award for his groundbreaking efforts to design novel drug therapies to treat chronic neurological disorders such as Alzheimer’s disease. The Prix Galien Awards are presented each year to honor outstanding achievements in the development of new medicines. Alzheimer’s disease is characterized by reduction of memory and cognitive skills through loss of or impaired function of synaptic connections in the brain. Dr. Weaver has worked to advance a research platform to develop therapeutic options focused on cellular pathways and targets that, if modulated, may halt disease progression or improve cognitive function.

Back to news